Floatz logo

Tinengotinib

Cholangiocarcinoma

TransThera Sciences (Nanjing), Inc.Small moleculePhase 3Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
73/ 100

Competitive context

92 Active assets in the Cholangiocarcinoma cohort.

Asset / SponsorPhaseRating
Eloxatin
Jonsson Comprehensive Cancer Center
Phase 3BB
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 3BB
Irinotecan
Jonsson Comprehensive Cancer Center
Phase 3B
ETOMIDATE
Cheju Halla General Hospital
Phase 4B
Docetaxel
Merck Sharp & Dohme LLC
Phase 2B

View all 50 →

Same molecule, other indications

Tinengotinib is also rated in:

triple-negative breast carcinomaDormant
B
Indicative ·
57 / 100
View asset →
cancerDormant
CCC
Indicative ·
55 / 100
View asset →
gallbladder cancerDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →